Notably, when CD8+ T-cells were depleted, silvestrol no longer provided effective anti-tumor protection (0/4 surviving in silvestrol-treated CD8-depleted group versus 4/4 in the silvestrol-treated mock-depleted group; p=0.029), nor did it reduce tumor burden as measured by spleen mass (not shown). Here, CD8A is linked to neoplasm.